What is the clinical evidence from this study?

Population: Hypertrophic obstructive cardiomyopathy (HOCM) (n=10). Intervention: Cibenzoline vs. Baseline (before administration). Primary outcome: Left ventricular pressure gradient (LVPG) (p=.0026).

What question did this study set out to answer?

To evaluate whether cibenzoline, a class Ia antiarrhythmic drug with minimal anticholinergic activity, reduces the left ventricular pressure gradient in patients with hypertrophic obstructive cardiomyopathy.

September 2, 1997Circulation

Class Ia Antiarrhythmic Drug Cibenzoline

View Full Paper

Ask AI

Bookmark

Key result

A single oral dose of cibenzoline significantly decreased left ventricular pressure gradient in patients with HOCM from 123 to 39 mm Hg (P=.0026).

Why the study?

Does cibenzoline reduce left ventricular pressure gradient in patients with hypertrophic obstructive cardiomyopathy?

Population

10 patients with hypertrophic obstructive cardiomyopathy (HOCM), mean age 59+/-12 years.

Comparison

Single oral dose of 150 or 200 mg cibenzoline vs Baseline (before administration)

Design

Case_series

Follow-up

2 hours (with mention of long-term treatment)

Authors

MHMareomi HamadaUwajima City Hospital YSYuji ShigematsuEhime University SIShuntaro IkedaKurume University

Discussion

Member takes

Implication

May support cibenzoline in HOCM; hypothesis-generating case report leaves clinical role open pending trials.

Key Points

To evaluate whether cibenzoline, a class Ia antiarrhythmic drug with minimal anticholinergic activity, reduces the left ventricular pressure gradient in patients with hypertrophic obstructive cardiomyopathy.
Interventional study in 10 patients with hypertrophic obstructive cardiomyopathy (mean age, 59±12 years).
Left ventricular pressure gradient and left ventricular function were evaluated before and 2 hours after a single oral dose of 150 or 200 mg cibenzoline, with additional long-term follow-up.
Left ventricular pressure gradient decreased significantly from 123±60 to 39±33 mm Hg (P=0.0026) following cibenzoline administration.
Left ventricular systolic dimension increased from 21.6±2.4 to 26.2±3.3 mm (P=0.0004), while fractional shortening dropped from 47.6±6.1% to 34.6±8.8% (P=0.0007).
Transmitral Doppler E/A ratio rose from 1.20±0.84 to 2.00±1.72 (P=0.029), isovolumic relaxation time lengthened from 73±16 to 101±23 ms (P=0.0026), and pressure gradient reduction persisted during long-term treatment.

Structured PICO

Does cibenzoline reduce left ventricular pressure gradient in patients with hypertrophic obstructive cardiomyopathy?

Population

10 patients with hypertrophic obstructive cardiomyopathy (HOCM), mean age 59+/-12 years.

Intervention

Single oral dose of 150 or 200 mg cibenzoline

Comparator

Baseline (before administration)

Outcome

Left ventricular pressure gradient (LVPG) 2 hours after administrationsurrogate

Main Result

Absolute Event Rate: 39% vs 123%

p-value: p=.0026

Cibenzoline significantly reduces left ventricular pressure gradient in patients with hypertrophic obstructive cardiomyopathy by decreasing myocardial contractility.

Cite This Study

Hamada et al. (1997) studied Hypertrophic obstructive cardiomyopathy (HOCM) (n=10). Cibenzoline vs. Baseline (before administration) was evaluated on Left ventricular pressure gradient (LVPG) (p=.0026). A single oral dose of cibenzoline significantly decreased left ventricular pressure gradient in patients with HOCM from 123 to 39 mm Hg (P=.0026).

synapsesocial.com/papers/6a08db7e73760a4edcd6047c https://doi.org/10.1161/01.cir.96.5.1520

Topics

Echocardiography Hypertrophic cardiomyopathy

View Full Paper

Ask AI

Bookmark

Class Ia Antiarrhythmic Drug Cibenzoline

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Topics

Class Ia Antiarrhythmic Drug Cibenzoline

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider